AArkstore enterprise Aarkstore - Hepatitis B - Pipeline Review, H2 2014
Browse Full Report @ http://www.aarkstore.com/pharmaceuticals-healthcare/66234/hepatitis-b-pipelinereview-h2-2014
Published: Nov 2014 | 317 Pages PDF : $ 2000 | Site Licence: $ 4000 | Enterprise Wide Licence : $ 6000
Summary “Hepatitis B - Pipeline Review, H2 2014�, provides an overview of the Hepatitis Bs therapeutic pipeline. This Market Research Report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects.
AArkstore enterprise Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hepatitis B - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hepatitis B and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hepatitis B products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hepatitis B pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-
AArkstore enterprise strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatitis B - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Order full Report with TOC and Sample page visit: http://www.aarkstore.com/pharmaceuticals-healthcare/66234/hepatitis-b-pipeline-review-h22014
Table of Contents: List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Hepatitis B Overview 12 Therapeutics Development 13 Pipeline Products for Hepatitis B - Overview 13 Pipeline Products for Hepatitis B - Comparative Analysis 14 Hepatitis B - Therapeutics under Development by Companies 15 Hepatitis B - Therapeutics under Investigation by Universities/Institutes 23 Hepatitis B - Pipeline Products Glance 24 Late Stage Products 24 Clinical Stage Products 25 Early Stage Products 26 Unknown Stage Products 27 Hepatitis B - Products under Development by Companies 28 Hepatitis B - Products under Investigation by Universities/Institutes 36 Hepatitis B - Companies Involved in Therapeutics Development 37 Abivax 37
AArkstore enterprise AiCuris GmbH & Co. KG 38 Akshaya Bio Inc. 39 Alnylam Pharmaceuticals, Inc. 40 AlphaMab Co., Ltd 41 AltraVax Inc. 42 Amarna Therapeutics B.V. 43 Arrowhead Research Corporation 44 Assembly Biosciences, Inc. 45 Beijing Minhai Biotechnology Co., Ltd 46 Benitec Biopharma Limited 47 Big DNA Ltd. 48 BioDiem Ltd 49 List Of Tables Number of Products under Development for Hepatitis B, H2 2014 21 Number of Products under Development for Hepatitis B - Comparative Analysis, H2 2014 22 Number of Products under Development by Companies, H2 2014 24 Number of Products under Development by Companies, H2 2014 (Contd..1) 25 Number of Products under Development by Companies, H2 2014 (Contd..2) 26 Number of Products under Development by Companies, H2 2014 (Contd..3) 27 Number of Products under Development by Companies, H2 2014 (Contd..4) 28 Number of Products under Development by Companies, H2 2014 (Contd..5) 29 Number of Products under Development by Companies, H2 2014 (Contd..6) 30 Number of Products under Investigation by Universities/Institutes, H2 2014 31 List Of Figures Number of Products under Development for Hepatitis B, H2 2014 21 Number of Products under Development for Hepatitis B - Comparative Analysis, H2 2014 22 Number of Products under Development by Companies, H2 2014 23 Number of Products under Investigation by Universities/Institutes, H2 2014 31 Comparative Analysis by Late Stage Development, H2 2014 32 Comparative Analysis by Clinical Stage Development, H2 2014 33 Comparative Analysis by Early Stage Products, H2 2014 34 Assessment by Monotherapy Products, H2 2014 116 Assessment by Combination Products, H2 2014 117 Number of Products by Top 10 Targets, H2 2014 118
AArkstore enterprise Related Market Research reports: •
Corticosteroid-Responsive Dermatoses - Pipeline Review, H1 2014
•
Hematological Tumor - Pipeline Review, H1 2014
•
Inflammation - Pipeline Review, H1 2014
•
Opioid Induced Side Effects - Pipeline Review, H1 2014
•
Skin Infections - Pipeline Review, H1 2014
•
Restenosis - Pipeline Review, H1 2014
•
Tauopathies - Pipeline Review, H1 2014
•
Nasopharyngitis (Common Cold) - Pipeline Review, H1 2014
•
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Pipeline Review, H1 2014
•
Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2014
About Aarkstore Enterprise Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers Contact Details: Aarkstore Enterprise Phone: +91 9987295242 / 022-27564953 Email: enquiry@aarkstore.com Our Website: http://www.aarkstore.com Our Blog : http://www.aarkstore.com/blog/ Latest News : http://www.aarkstore.com/news Facebook: https://www.facebook.com/aarkstoredotcom
AArkstore enterprise